Find one near you.
To reduce the selection bias and observed confounding between the two groups, inverse probability of treatment weighting (IPTW) [21] was derived by conducting a regularized logistic regression with elastic net penalty on the semaglutide group vs DPP4i group with the following variables: age, race and ethnicity, index year, payer type, CCI, DCSI, glucose-lowering medications, baseline HbA1c level, baseline BMI and obesity diagnosis, health care utilization at baseline, comorbidities, and other medications at baseline
If you are using a program through TrimRx that utilizes Compounded Semaglutide or Compounded Tirzepatide, these are almost exclusively once-weekly injections
Retatrutide does not have FDA approval as of mid-2025
Getting your Trinity Audio player ready
PASMCs, Pulmonary artery smooth muscle cells